High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors

Summary

Endothelial progenitor cells (EPC) displaya unique ability to repair vascular injury and promote neovascularization although the underlying molecular mechanisms remain poorly understood. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play a critical role in cell migration and angiogenesis by facilitating proteolysis of extracellular matrix.The aim of the present study was to characterize the uPA/uPAR-dependent proteolytic potential of EPC outgrown from human umbilical cord blood and to analyze its contribution to their angiogenic properties in vitro. Cells derived from EPC (EPDC), presenting typical features of late outgrowth endothelial cells, were compared to mature endothelial cells, represented by human umbilical vein endothelial cells (HUVEC). Using quantitative flow cytometry, enzyme-linked immunosorbent assays and zymography, we demonstrated that EPDC displayed higher levels of uPA and uPAR. In conditioned culture media, uPA-dependant proteolytic activity was also found to be significantly increased in EPDC.This activity was paralleled bya higher secretion of pro-metalloproteinase-2 (pro-MMP-2). Inhibition of EPDC-associated uPA by monoclonal antibodies that block either uPA activity or receptor binding, significantly reduced proliferation, migration and capillary like tube formation. Moreover, tumor necrosis factoralpha and vascular endothelial growth factor,known to be locally secreted in ischemic areas, further increased the proteolytic potential of EPDC by up-regulating uPA and uPAR expression respectively.The EPDC response to these factors was found to be more pronounced than that of HUVEC. In conclusion, these findings indicated that EPDC are characterized by high intrinsic uPA/uPAR-dependent proteolytic potential that could contribute to their invasive and angiogenic behaviour.

Keywords

Endothelial progenitor - urokinase - angiogenesis - proteolysis

• References

• 1 Asahara T, Murohara T, Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
• 2 Shi Q, Rafii S, Wu MH. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-7.
• 3 Asahara T, Masuda H, Takahashi T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
• 4 Hill JM, Zalos G, Halcox JP. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
• 5 Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 08: 498-508.
• 6 Tateishi-Yuyama E, Matsubara H, Murohara T. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-35.
• 7 Schachinger V, Assmus B, Britten MB. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final oneyear results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-9.
• 8 Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-53.
• 9 Hur J, Yoon CH, Kim HS. et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-93.
• 10 He T, Peterson TE, Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells – Role of interleukin-8. Am J Physiol Heart Circ Physiol 2005; 289: H968-72.
• 11 He T, Peterson TE, Holmuhamedov EL. et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol 2004; 24: 2021-7.
• 12 Urbich C, Heeschen C, Aicher A. et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005; 11: 206-13.
• 13 Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
• 14 Parfyonova YV, Plekhanova OS, Tkachuk VA. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc) 2002; 67: 119-34.
• 15 Li H, Lu H, Griscelli F. et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998; 05: 1105-13.
• 16 Rakic JM, Lambert V, Munaut C. et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 1732-9.
• 17 Heymans S, Luttun A, Nuyens D. et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 05: 1135-42.
• 18 Jaffe EA, Nachman RL, Becker CG. et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 19 Delorme B, Sabatier F, Gentile C. et al. Presence of endothelial progenitor cells, distinct from matureendothelial cells, within human CD146+ blood cells. Thromb Haemost 2005; 94: 1270-9.
• 20 Camoin-Jau L, Pannell R, Anfosso F. et al. Platelet associated u-PA up-regulates u-PA synthesis by endothelial cells. Thromb Haemost 2002; 88: 517-23.
• 21 Herron GS, Banda MJ, Clark EJ. et al. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261: 2814-8.
• 22 Mazzieri R, Masiero L, Zanetta L. et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Embo J 1997; 16: 2319-32.
• 23 Bompais H, Chagraoui J, Canron X. et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004; 103: 2577-84.
• 24 Gulati R, Jevremovic D, Peterson TE. et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93: 1023-5.
• 25 Ingram DA, Mead LE, Tanaka H. et al. Identification ofa novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
• 26 Tepper OM, Capla JM, Galiano RD. et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005; 105: 1068-77.
• 27 Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004; 287: C572-9.
• 28 Kocher AA, Schuster MD, Szabolcs MJ. et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 07: 430-6.
• 29 Madeddu P, Emanueli C, Pelosi E. et al. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. Faseb J 2004; 18: 1737-9.
• 30 Ott I, Keller U, Knoedler M. et al. Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. Faseb J 2005; 19: 992-4.
• 31 Takahashi K, Uwabe Y, Sawasaki Y. et al. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 1998; 275 (1 Pt 1) L47-54.
• 32 Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997; 110 ( Pt 18) 2293-302.
• 33 Kroon ME, Koolwijk P, van der Vecht B. et al. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 2000; 96: 2775-83.
• 34 Gualandris A, Lopez TConejo, Giunciuglio D. et al. Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. Microvasc Res 1997; 53: 254-60.
• 35 Koolwijk P, Kapiteijn K, Molenaar B. et al. Enhanced angiogenic capacity and urokinase-type plasminogen activator expression by endothelial cells isolated from human endometrium. J Clin Endocrinol Metab 2001; 86 (07) 3359-67.
• 36 Alfano D, Franco P, Vocca I. et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005; 93: 205-11.
• 37 Padro T, Mesters RM, Dankbar B. et al. The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells. J Cell Sci 2002; 115 Pt 09 1961-71.
• 38 Kirchheimer JC, Wojta J, Christ G. et al. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci U S A 1989; 86: 5424-8.
• 39 Kim KS, Hong YK, Lee Y. et al. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp Mol Med 2003; 35: 578-85.
• 40 Lu H, Mabilat C, Yeh P. et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996; 380 1–2 21-4.
• 41 Schnaper HW, Barnathan ES, Mazar A. et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107-18.
• 42 Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001; 81 (04) 439-52.
• 43 Xiang G, Schuster MD, Seki T. et al. Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. J Exp Med 2004; 200: 1657-66.
• 44 Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005; 106: 1525-31.
• 45 Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90: 3579-86.
• 46 Tamura M, Unno K, Yonezawa S. et al. In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization. Life Sci 2004; 75: 575-84.
• 47 Yoon CH, Hur J, Park KW. et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112: 1618-27.
• 48 Niedbala MJ, Picarella MS. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood 1992; 79: 678-87.
• 49 Chen JX, Chen Y, DeBusk L. et al. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol 2004; 287: H187-95.
• 50 Koolwijk P, van Erck MG, de Vree WJ. et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.